388 related articles for article (PubMed ID: 22845401)
21. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
24. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Kim MJ; Choi JI; Lee JS; Park JW
J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
[TBL] [Abstract][Full Text] [Related]
25. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Koschny R; Gotthardt D; Koehler C; Jaeger D; Stremmel W; Ganten TM
Oncology; 2013; 84(1):6-13. PubMed ID: 23075905
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
27. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Iavarone M; Cabibbo G; Piscaglia F; Zavaglia C; Grieco A; Villa E; Cammà C; Colombo M;
Hepatology; 2011 Dec; 54(6):2055-63. PubMed ID: 21898496
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M
Oncology; 2013; 84(2):108-14. PubMed ID: 23147476
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
32. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
33. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Song T; Zhang W; Wu Q; Kong D; Ma W
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
[TBL] [Abstract][Full Text] [Related]
34. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
35. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Miyahara K; Nouso K; Tomoda T; Kobayashi S; Hagihara H; Kuwaki K; Toshimori J; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Yamamoto K
J Gastroenterol Hepatol; 2011 Nov; 26(11):1604-11. PubMed ID: 22011296
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Doyle A; Marsh P; Gill R; Rodov M; Mohsen W; Varma P; Hong T; Strasser SI; Bell S; Ryan M; Nicoll A; Lubel J; Gow PJ; Fink MA; Roberts S; Kemp W; Kronborg I; Arachchi N; Knight V; Dev A
Scand J Gastroenterol; 2016 Aug; 51(8):979-85. PubMed ID: 27161568
[TBL] [Abstract][Full Text] [Related]
37. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Raoul JL; Bruix J; Greten TF; Sherman M; Mazzaferro V; Hilgard P; Scherubl H; Scheulen ME; Germanidis G; Dominguez S; Ricci S; Nadel A; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 May; 56(5):1080-1088. PubMed ID: 22245896
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
39. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
